SCHEMBL21704217

SCHEMBL21704217

CCn1ccc2cc(C)nnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
ATM Q13315 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LMNA P02545 2/20 0.31
ABCC4 O15439 1/20 0.31
PKM P14618 1/20 0.31
PTGS1 P23219 1/20 0.31
ALDH1A1 P00352 2/20 0.31
GAA P10253 1/20 0.31
CYP19A1 P11511 1/20 0.30
CYP1A2 P05177 1/20 0.30
NFKB1 P19838 1/20 0.30
BLM P54132 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23938065 0.80 KDM4E (0.33) MAPTKDM4EMEN1KMT2A
SCHEMBL20722578 0.80 HTR2A (0.34) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL20731185 0.80 PIK3CB (0.35) MAPTKDM4EMEN1KMT2A
SCHEMBL20722463 0.76 KMT2A (0.37) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL21704264 0.75 KCNJ1 (0.34) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL30741071 0.74 LCK (0.37) KDM4EKMT2ALMNA
SCHEMBL25889320 0.73 MEN1 (0.42) MAPTKDM4EMEN1KMT2ARAB9A
SCHEMBL21704227 0.73 CCR1 (0.42) MAPTKDM4EMEN1KMT2ACYP19A1
SCHEMBL23938018 0.72 HTR2A (0.33) MAPTKDM4EMEN1KMT2ACYP19A1
SCHEMBL20722848 0.72 PTGER4 (0.39) MAPTKDM4ESMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 MAPT 2661/4885KDM4E 403/4885MEN1 3554/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 MAPT 2661/4885KDM4E 403/4885MEN1 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.